Sort
30,917 grants matching “tumor microenvironment”
PTEN, Tregs and MDSCs in the tumor microenvironment
$347,700David H Munn · Augusta University · R01 · FY2017 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
PTEN, Tregs and MDSCs in the tumor microenvironment
$347,700David H Munn · Augusta University · R01 · FY2018 · CA
PTEN, Tregs and MDSCs in the tumor microenvironment
$347,700David H Munn · Augusta University · R01 · FY2021 · CA
Stealth Brusatol and Docetaxel-loaded Nanoparticles for Targeted Prostate Cancer Therapy
$347,625Simeon Kolawole Adesina · Howard University · SC1 · FY2021 · GM
Polyamine and Glutamate Driven Interactions in the Glioblastoma-Brain Microenvironment
$347,621Scott Michael Welford · University Of Miami School Of Medicine · R01 · FY2021 · CA
Polyamine and Glutamate Driven Interactions in the Glioblastoma-Brain Microenvironment
$347,621Scott Michael Welford · University Of Miami School Of Medicine · R01 · FY2025 · CA
Locally Targeted Off-The-Shelf NK Cells For Ovarian Cance
$347,612Melissa Ann Geller · University Of Minnesota · P01 · FY2024 · CA
High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer
$347,533Dolores Di Vizio · Cedars-Sinai Medical Center · R01 · FY2020 · CA
Identification of USP13 as a therapeutic target for ovarian cancer
$347,513Xiongbin Lu · Indiana University Indianapolis · R01 · FY2022 · CA
Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy
$347,511Zachary Scott Morris · University Of Wisconsin-Madison · P50 · FY2025 · CA
Development of a targeted delivery platform for checkpoint inhibitors
$347,471Kun Cheng · University Of Missouri Kansas City · R01 · FY2022 · CA
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
$347,471Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2022 · CA
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
$347,471Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2023 · CA
Inhibition of angiogenesis by thrombospondin-1 (A2)
$347,364John W Lawler · Beth Israel Deaconess Medical Center · R01 · FY2012 · CA
Personalization and Failure Testing of Dual Switch Gene Drives in Lung Cancer
$347,360Justin Pritchard · Pennsylvania State University, The · U01 · FY2025 · CA
Cancer Immunology Training Program
$347,342Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · T32 · FY2022 · CA
The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDSC development
$347,319Tracy L McGaha · Augusta University · R01 · FY2015 · CA
Human papillomavirus in HIV associated lung cancers
$347,257Zhen Lin · Tulane University Of Louisiana · R01 · FY2025 · CA
Human papillomavirus in HIV associated lung cancers
$347,257Zhen Lin · Tulane University Of Louisiana · R01 · FY2023 · CA
Human papillomavirus in HIV associated lung cancers
$347,257Zhen Lin · Tulane University Of Louisiana · R01 · FY2024 · CA
Targeting TIGIT and PD-1 in Melanoma
$347,253Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA
Influence of hemodynamic shear stress on circulating tumor cells
$347,251Michael D. Henry · University Of Iowa · R01 · FY2024 · CA
Microenvironmental Control of Capillary Morphogenesis
$347,245Andrew J Putnam · University Of Michigan At Ann Arbor · R01 · FY2017 · HL
Effects of extracellular vesicles on miRNA activity in the skin
$347,240My Georgia Mahoney · Thomas Jefferson University · R01 · FY2020 · AR